Coronavirus Disease (COVID-19) in Cancer Patients: A Systematic Review and Meta-Analysis to Evaluate Severity and Fatal Outcomes

2020 ◽  
Author(s):  
Abhijeet Ashok Salunke ◽  
Kunal Nandy ◽  
Subodh Kumar Pathak ◽  
Ketul Puj ◽  
Vikas Warikoo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Patients ◽  
Meta Analysis

Effectiveness of five-element music therapy in cancer patients: A systematic review and meta-analysis

2021 ◽  
pp. 101416
Author(s):  
Ting Yang ◽  
Shurui Wang ◽  
Ruirui Wang ◽  
Yuqi Wei ◽  
Yannan Kang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Music Therapy ◽  
Cancer Patients ◽  
Meta Analysis

Traditional Oriental Herbal Medicine and Natural Killer Cells for Cancer Patients: A Systematic Review and Meta-analysis

2017 ◽  
Vol 31 (4) ◽  
pp. 519-532 ◽  
Author(s):  
Kyeore Bae ◽  
Ji-hye Park ◽  
Jeehye Kim ◽  
Chong-kwan Cho ◽  
Byeongsang Oh ◽  
...  
Keyword(s):  
Systematic Review ◽  
Natural Killer Cells ◽  
Herbal Medicine ◽  
Natural Killer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Killer Cells

scholarly journals Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a protocol for a systematic review and network meta-analysis

BMJ Open ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. e033461
Author(s):  
Kyeore Bae ◽  
Si Yeon Song
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Pain Intensity ◽  
Aromatase Inhibitor ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Indirect Evidence ◽  
Secondary Outcome ◽  
Breast Cancer Patients ◽  
Patient Reported

IntroductionAromatase inhibitor-induced arthralgia (AIA) is a major adverse event of aromatase inhibitors (AIs) and leads to premature discontinuation of AI therapy in breast cancer patients. The objective of this protocol for a systematic review and network meta-analysis (NMA) is to provide the methodology to compare the change in pain intensity between different AIA treatments and demonstrate the rank probabilities for different treatments by combining all available direct and indirect evidence.Methods and analysisPubMed, the Cochrane Controlled Register of Trials (CENTRAL), EMBASE, Web of Science and ClinicalTrials.gov will be searched to identify publications in English from inception to November 2019. We will include randomised controlled trials (RCTs) assessing the effects of different treatments for AIA in postmenopausal women with stage 0–III hormone receptor-positive breast cancer. The primary endpoints will be the change in patient-reported pain intensity from baseline to post-treatment. The number of adverse events will be presented as a secondary outcome.Both pairwise meta-analysis and NMA with the Frequentist approach will be conducted. We will demonstrate summary estimates with forest plots in meta-analysis and direct and mixed evidence with a ranking of the treatments as the P-score in NMA. The revised Cochrane risk-of-bias tool for randomised trials will be used to assess the methodological quality within individual RCTs. The quality of evidence will be assessed.Ethics and disseminationAs this review does not involve individual patients, ethical approval is not required. The results of this systematic review and NMA will be published in a peer-reviewed journal. This review will provide valuable information on AIA therapeutic options for clinicians, health practitioners and breast cancer survivors.PROSPERO registration numberCRD42019136967.

Sign in / Sign up

Export Citation Format

Share Document